Personal information

Rodrigo Eduardo Pacheco Pérez.
Medical Oncologist, focusing on digestiv and hepatobiliary tumors
Professional ID: 6332236
Specialist ID: 9988280
Mexican Council of Oncology 1497
Email: rodrigopacheco.onco@gmail.com        
Teléfono: (999) 91 220439

Education:

Bachelor´s:
Surgeon General by Facultad de Medicina de la Universidad Autonoma de Yucatan.
Bachelor's: Surgeon General by Facultad de Medicina de la Universidad Autonoma de Yucatan.

Postgraduate::

  1. Two years experience of Internal Medicine at Instituto del Seguro Social
    1. First year: General Hospital of Zone #16 IMSS, Torreón, Coahuila.
    2. Second year: High Specialty Medical Unit #71 IMSS, Torreón, Coahuila.
  2. Degree on Oncology by Centro Médico Nacional Siglo XXI, Hospital de Oncología at Instituto Mexicano del Seguro Social.
  3. Master in Digestives and Hepatobilliary cancer at Universidad Cardenal Herrera.

Language

English: spoken 80%, translate 90%, write 80%

Professional and Academic Experience:

  • Oncologist at Centro Medico de las Americas (CMA), Merida, Yucatan
  • Surrogate Oncologist at the healthe service of Universidad Autonoma de Yucatan
  • Oncologist at the service of Medical Oncology at Hospital Regional Mérida from ISSSTE
  • Professor of Oncology at Facultad de Medicina de la Universidad Autónoma de Yucatán
  • Principal Investigator of clinical trials.
  • .
  • Update Courses or Training received.
    • Certificación en Oncología Médica en 2015, por el Consejo Mexicano de Oncología A.C.
    • Certificación en Oncología Médica en 2020, por el Consejo Mexicano de Oncología A.C.
  • Actividades Docentes, Asistenciales o de Investigación.
    • Head of Undergraduate Medical Interns at the Universidad Autonoma de Yucatan, during the rotating internship at Hospital O'Horan during the period 2007-2008.
    • Head of Residents of the 1st year of Internal Medicine at Hospital General Zone #16, Instituto Mexicano del Seguro Social, Torreón, Coahuila, period 2010-2011.
    • Participation as sub-investigator in the international study: A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE).
    • Participation as sub-investigator in the international study: Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC (CheckMate 057).
    • Degree thesis of specialty in Medical Oncology in 2015: Overall Survival in Patients with Clinical Stage IIIB and IV Non-Small Cell Lung Cancer Treated at the CMN SXXI Oncology Hospital in the Period From 2009 to 2011
    • Professor at the Oncological Nutrition Seminar of EP in Mexico in October 2016.
    • Principal investigator in the international study: Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer (IPATential150). Currently in progress.
    • Principal investigator in the international study: Phase III, randomized, double-blind, placebo-controlled study of Ipatasertib in combination with paclitaxel for the treatment of patients with triple-negative breast cancer or hormone receptor-positive and HER2-negative breast cancer, in both cases locally advanced or metastatic and with alteration of PIK3CA/AKT1/PTEN (IPATUNITY).
    • Principal Investigator in International Study: Multicenter, Single-Arm Phase III/IV Study to Investigate the Long-Term Safety and Efficacy of Atezolizumab (Tencentriq) in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TAIL).
    • Principal Investigator in International Study (WO39391): Phase III, Multicenter, Randomized, Open-label Study Comparing Atezolizumab (Anti-PD-L1 Antibody) in Combination with anthracycline-based/taxane-based adjuvant chemotherapy versus chemotherapy alone in cancer patients triple negative operable breast cancer (IMpasssion 131). Currently in progress.
    • Principal investigator in the international study: MonarchE (I3Y-MC-JPCF): “Randomized, open-label phase 3 study of abemaciclib in combination with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy monotherapy, in breast cancer patients in early stages, high risk, with lymph node involvement, positive hormone receptors, HER2 negative.” Currently in progress.
    • Investigador principal en el estudio internacional CheckMate 9ER: A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma. Actualmente en curso.
  • Publications
    • The multidisciplinary treatment of hepatocarcinoma and metastatic renal cancer. Conclusions of the first IMSS-ISSSTE interinstitutional meeting. Journal of medical-surgical specialties 2018;23(3):139-144.
    • Epidemiological registry of malignant neoplasms in two hospitals in Yucatan in the period from January 2015 to December 2017. Journal of medical-surgical specialties 2019;24:48-56.
Contact me
× Contact